ReviewJournal of clinical medicine2021
Therapeutic Targets and Tumor Microenvironment in Colorectal Cancer.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Article
- The Interplay of CD8+ TILs and Microvascular Density: A Novel Prognostic Indicator in Colorectal Adenocarcinoma.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Multi-Phasic CECT Peritumoral Radiomics Predict Treatment Response to Bevacizumab-Based Chemotherapy in RAS-Mutated Colorectal Liver Metastases.Bioengineering (Basel, Switzerland) · 2026Article
- Contrasting Prognostic Roles of Stromal Periostin Expression and Immune Cells Infiltration in Colorectal Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Biogenic synthesis of gold nanoparticles using Coleus forskohlii leaf extract enhances anticancer activity against HT-29 cells and modulates the p53 regulated immune microenvironment in colon adenocarcinoma.Scientific reports · 2026Article
- Multifaceted Attack Networks of Artemisinin in Reversing Chemoresistance in Colorectal Cancer.Molecules (Basel, Switzerland) · 2026Review
- Melatonin at the Crossroads of Oxidative Stress, Immunity, and Cancer Therapy.Antioxidants (Basel, Switzerland) · 2026Review
- Myeloid-derived suppressor cells in colorectal cancer: mechanisms of immunosuppression, therapy resistance and therapeutic targeting.Frontiers in cell and developmental biology · 2026Review
- Identification of super-enhancer-based biomarkers for predicting survival and immunotherapy efficacy in colorectal cancer.Journal of Cancer · 2026Article
- Comparative Analysis of Tumor-Immune Microenvironment Diversity Among Biopsy, Resection, and Metastatic Colorectal Cancer Specimens.Journal of immunology research · 2026Article
- CXCL10/CXCR3 axis facilitates the M2 polarization of macrophages in colorectal cancer via activating RAF.Discover oncology · 2025Article
- Immunostimulatory effects of IL-12 targeted pH-responsive nanoparticles in macrophage-enriched 3D immuno-spheroids in vitro model.Drug delivery and translational research · 2025Article
- Can Salivary Biomarkers Serve as Diagnostic and Prognostic Tools for Early Detection in Patients with Colorectal Cancer? A Systematic Review.Current issues in molecular biology · 2025Review
- Investigating the potential role of miR-451a as a tumor suppressor in immunogenic cell death induction and dendritic cell maturation in colorectal cancer cell lines.Cancer cell international · 2025Article
- Piperine Induces Apoptosis and Cell Cycle Arrest via Multiple Oxidative Stress Mechanisms and Regulation of PI3K/Akt and MAPK Signaling in Colorectal Cancer Cells.Antioxidants (Basel, Switzerland) · 2025Article
- Adoptive cell therapy in colorectal cancer: Advances in chimeric antigen receptor T cells.World journal of gastrointestinal oncology · 2025Review
- Article
- Minimally Invasive Rectal Surgery: Current Status and Future Perspectives in the Era of Digital Surgery.Journal of clinical medicine · 2025Review
- Targeting SLC4A4: A Novel Approach in Colorectal Cancer Drug Repurposing.Current issues in molecular biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a genetically, anatomically, and transcriptionally heterogeneous disease. The prognosis for a CRC patient depends on the stage of the tumor at diagnosis and widely differs accordingly. The tumor microenvironment (TME) in CRC is an important factor affecting targeted cancer therapy. The TME has a dynamic composition including various cell types, such as cancer-associated fibroblasts, tumor-associated macrophages, regulatory T cells, and myeloid-derived suppressor cells, as well as extracellular factors that surround cancer cells and have functional and structural roles under physiological and pathological conditions. Moreover, the TME can limit the efficacy of therapeutic agents through high interstitial pressure, fibrosis, and the degradation of the therapeutic agents by enzymatic activity. For this reason, the TME is a fertile ground for the discovery of new drugs. The aim of this narrative review is to present current knowledge and future perspectives regarding the TME composition based on strategies for patients with CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.